vestor111 wrote: Hey Ulf
In a nutshell. (I haven't re-read this. Sorry, I find this format tedious as I type from across the room and I need more coffee.)
It appears Roswell Park Comprehensive Cancer Center has developed a PDT fiber activator/dosimetry device and has a NIH research grant to study its use. RSCCC is only about 50 miles from Toronto and is probably in close contact with UHN and TLT.
They appear to have used some of this grant money to study 1433 and appear to have reached out to Dr McFarland in support of the research (this could have been the other way around, either they tied up).
No one from TLT is an author on the paper but fear not, TLT has worldwide rights to 1433 (many other of Dr M's magic compounds) so it appears TLT may now have a very willing partner to initiate a NSCLC trial study. Weather RPCCC moves ahead on their own with a licensing agreement with TLT 1433 remains to be seen.
The paper clearly states animal studies are planned. I did find a paper on the use of mice in lung cancer research but if mice are suitable for the OSA isn't clear.
The proper use and teating of this device seems to make RPCCC the proper group to lead further study and possibly take the lead in any human trial. Quoting:
More work is underway to test our treatment planning and tumor response to TLD1433-
mediated IO-PDT in the thoracic cavity of animal models.
It seems that based on this, RPCCC maybe leading this via the use of their device perhaps backed up by NIH funding.
One must think TLT is fully aware of this research and is perhaps in discussions on a licensing/usage arrangement with RSCCC and possible ways to support the further research.
Discussion:
1. Green Light: RSCCC/Dr M once again find green light as the best wavelength for activation. Finding that greenlight allows 1. low dosage levels, 2. much lower activation level (ie less phototonic energy is needed presumably with less collateral tissue damage) and 3. green light has a 3mm depth of tissue penetration - making it very suitible for larger NSCLC tumor sizes.
2. Animals studies: "more work is underway." As was as I have noted what animal model will be used may require air passages large than the standardized mouse model. (I am not sure when this selection will be disclosed but it is "underway." How far along they are at this point is unknown but it would appear results could be acheived fairly "quickly" since various animals models have existed for research for many years.
Once an animal model(s) is selected, prepping and "infecting" the model is probably alos fairly standardized by researchers.
Once the animal model(s) are "infected", treatment can be attempted. Given the speedy nature of the treatment therapy, one might expect result could be compiled fairly "quickly" as well. (I hope some of the model subjects will be allowed to "retire" to see how long and how thorough the therapy could achieve.)
3. Compound supply: I didn't see (but have not finished reading late last night the entire paper - the implications were too exciting) whether TLT supplied the compound from their stocks (ie as might be used in the NMIBC studies) but if not at this stage might not be an issue although as the science progress, using the off the shelve stocking might assure closer alignment to "reality."
4. Patents: Both the researchers from RPCC who invented the OSA device appear to have lead the research and are noted as the patent recipients.
Quoting:
G.S. and D.B. are co-inventors of a patent application owned by Roswell Park for the OSA that was licensed to Lumeda Inc. S.A.M. is the inventor of two issued patents
(9,345,769 and 9,676,806 B2) for TLD1433 that are licensed to Theralase Technologies, Inc.
4. Future Human Trials: It appears that due to the nature of the device and its proper use, RPCCC might be the lead advocate for any human study. If this proves true, it a MAJOR DEVELOPMENT for TLT!
5. Device Development: One issue that has concerned me over the years is the ongoing role of Dr Lilge and Betz and whether their work could become a bottleneck. The concern stems from the notion that every indication may need a specialized device - designed, tested and approved by Dr Lilge with Betz in support of model simulation. Both are fairly tall orders and clearly Dr Lilge does a lot of research on a variety of topics in photonic dosimetry. This concern is no more and could lead to other parallel research efforts to get on the 1433 research train.
There maybe some additional points to highlight but I think that covers the main takeaways from my prespective.
In short, THIS IS HUGE in my opinion. Very huge!
Joe/Vestor
PS We are closer to that dinner in Stockholm it appears!